Onconetix (ONCO) Competitors

$1.24 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$1.30 +0.06 (+4.52%)

As of 05/22/2026 07:59 PM Eastern

ONCO vs. AMPE, PTPI, VINC, VAXX, and ADTX

Should you buy Onconetix stock or one of its competitors? MarketBeat compares Onconetix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Onconetix include Ampio Pharmaceuticals (AMPE), Petros Pharmaceuticals (PTPI), Vincerx Pharma (VINC), Vaxxinity (VAXX), and Aditxt (ADTX). These companies are all part of the "pharmaceutical products" industry.

How does Onconetix compare to Ampio Pharmaceuticals?

Ampio Pharmaceuticals (NYSE:AMPE) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ampio Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Ampio Pharmaceuticals has a beta of 5.96, suggesting that its stock price is 496% more volatile than the broader market. Comparatively, Onconetix has a beta of 3.01, suggesting that its stock price is 201% more volatile than the broader market.

Ampio Pharmaceuticals has higher earnings, but lower revenue than Onconetix. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A
Onconetix	$810K	1.75	-$14.03M	$11.40	0.11

Ampio Pharmaceuticals has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Ampio Pharmaceuticals' return on equity of 0.00% beat Onconetix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Onconetix	-1,316.28%	-101.08%	-47.34%

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Onconetix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Onconetix had 5 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 5 mentions for Onconetix and 0 mentions for Ampio Pharmaceuticals. Ampio Pharmaceuticals' average media sentiment score of 0.00 beat Onconetix's score of -0.40 indicating that Ampio Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Ampio Pharmaceuticals	Neutral
Onconetix	Neutral

Summary

Ampio Pharmaceuticals beats Onconetix on 7 of the 13 factors compared between the two stocks.

How does Onconetix compare to Petros Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 23.9% of Onconetix shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by company insiders. Comparatively, 0.3% of Onconetix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Petros Pharmaceuticals has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Petros Pharmaceuticals' return on equity of -78.22% beat Onconetix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Onconetix	-1,316.28%	-101.08%	-47.34%

In the previous week, Onconetix had 5 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 5 mentions for Onconetix and 0 mentions for Petros Pharmaceuticals. Petros Pharmaceuticals' average media sentiment score of 0.00 beat Onconetix's score of -0.40 indicating that Petros Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Onconetix	Neutral

Petros Pharmaceuticals has higher revenue and earnings than Onconetix. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$1.64	N/A
Onconetix	$810K	1.75	-$14.03M	$11.40	0.11

Petros Pharmaceuticals has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market. Comparatively, Onconetix has a beta of 3.01, meaning that its stock price is 201% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Petros Pharmaceuticals and Onconetix tied by winning 7 of the 14 factors compared between the two stocks.

How does Onconetix compare to Vincerx Pharma?

Onconetix (NASDAQ:ONCO) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

In the previous week, Onconetix had 5 more articles in the media than Vincerx Pharma. MarketBeat recorded 5 mentions for Onconetix and 0 mentions for Vincerx Pharma. Vincerx Pharma's average media sentiment score of 0.00 beat Onconetix's score of -0.40 indicating that Vincerx Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Onconetix	Neutral
Vincerx Pharma	Neutral

23.9% of Onconetix shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 0.3% of Onconetix shares are held by insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Onconetix has higher revenue and earnings than Vincerx Pharma. Vincerx Pharma is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810K	1.75	-$14.03M	$11.40	0.11
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

Onconetix has a beta of 3.01, indicating that its share price is 201% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

Vincerx Pharma has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Onconetix's return on equity of -101.08% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,316.28%	-101.08%	-47.34%
Vincerx Pharma	N/A	-248.33%	-132.73%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vincerx Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Onconetix beats Vincerx Pharma on 9 of the 13 factors compared between the two stocks.

How does Onconetix compare to Vaxxinity?

Vaxxinity (NASDAQ:VAXX) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Onconetix has higher revenue and earnings than Vaxxinity. Vaxxinity is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A
Onconetix	$810K	1.75	-$14.03M	$11.40	0.11

Vaxxinity has a beta of -74.37, meaning that its share price is 7,537% less volatile than the broader market. Comparatively, Onconetix has a beta of 3.01, meaning that its share price is 201% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxxinity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

82.9% of Vaxxinity shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by insiders. Comparatively, 0.3% of Onconetix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Vaxxinity has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Vaxxinity's return on equity of 0.00% beat Onconetix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxxinity	N/A	N/A	N/A
Onconetix	-1,316.28%	-101.08%	-47.34%

In the previous week, Onconetix had 4 more articles in the media than Vaxxinity. MarketBeat recorded 5 mentions for Onconetix and 1 mentions for Vaxxinity. Vaxxinity's average media sentiment score of 0.00 beat Onconetix's score of -0.40 indicating that Vaxxinity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxxinity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Onconetix	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Onconetix beats Vaxxinity on 7 of the 13 factors compared between the two stocks.

How does Onconetix compare to Aditxt?

Onconetix (NASDAQ:ONCO) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

23.9% of Onconetix shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 0.3% of Onconetix shares are owned by insiders. Comparatively, 0.0% of Aditxt shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Onconetix has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810K	1.75	-$14.03M	$11.40	0.11
Aditxt	N/A	N/A	-$41.71M	-$11.10 thousand	N/A

Onconetix has a beta of 3.01, suggesting that its share price is 201% more volatile than the broader market. Comparatively, Aditxt has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Onconetix has a net margin of -1,316.28% compared to Aditxt's net margin of -360,152.50%. Onconetix's return on equity of -101.08% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,316.28%	-101.08%	-47.34%
Aditxt	-360,152.50%	-839.49%	-105.93%

In the previous week, Onconetix had 3 more articles in the media than Aditxt. MarketBeat recorded 5 mentions for Onconetix and 2 mentions for Aditxt. Aditxt's average media sentiment score of 1.00 beat Onconetix's score of -0.40 indicating that Aditxt is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Onconetix	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aditxt	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Onconetix beats Aditxt on 11 of the 12 factors compared between the two stocks.

Get Onconetix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONCO vs. The Competition

Export

Metric	Onconetix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.41M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	0.11	18.74	21.00	25.66
Price / Sales	1.75	323.98	558.19	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	0.12	7.09	10.40	7.14
Net Income	-$14.03M	$24.45M	$3.57B	$335.98M
7 Day Performance	5.53%	6.38%	6.40%	4.11%
1 Month Performance	-78.89%	2.43%	3.55%	2.52%
1 Year Performance	-99.60%	62.98%	34.13%	35.04%

Onconetix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONCO Onconetix	1.3658 of 5 stars	$1.24 flat	N/A	-99.6%	$1.41M	$810K	0.11	12	Analyst Downgrade Stock Split Gap Down
AMPE Ampio Pharmaceuticals	N/A	$0.18 flat	N/A	N/A	$208K	N/A	N/A	20
PTPI Petros Pharmaceuticals	N/A	$0.01 -9.0%	N/A	-84.4%	$190K	$5.11M	N/A	20	Gap Up
VINC Vincerx Pharma	N/A	$0.01 flat	N/A	-73.9%	$66K	N/A	N/A	60
VAXX Vaxxinity	N/A	$0.00 flat	N/A	+0.0%	$63K	N/A	N/A	90	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONCO) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Onconetix (ONCO) Competitors

ONCO vs. AMPE, PTPI, VINC, VAXX, and ADTX

How does Onconetix compare to Ampio Pharmaceuticals?

Summary

How does Onconetix compare to Petros Pharmaceuticals?

Summary

How does Onconetix compare to Vincerx Pharma?

Summary

How does Onconetix compare to Vaxxinity?

Summary

How does Onconetix compare to Aditxt?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO vs. The Competition

Onconetix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Onconetix (ONCO) Competitors

ONCO vs. AMPE, PTPI, VINC, VAXX, and ADTX

How does Onconetix compare to Ampio Pharmaceuticals?

Do analysts rate AMPE or ONCO?

Which has more risk & volatility, AMPE or ONCO?

Which has preferable valuation & earnings, AMPE or ONCO?

Is AMPE or ONCO more profitable?

Do institutionals & insiders have more ownership in AMPE or ONCO?

Does the media prefer AMPE or ONCO?

Summary

How does Onconetix compare to Petros Pharmaceuticals?

Do insiders and institutionals hold more shares of PTPI or ONCO?

Is PTPI or ONCO more profitable?

Does the media prefer PTPI or ONCO?

Which has stronger earnings and valuation, PTPI or ONCO?

Which has more risk & volatility, PTPI or ONCO?

Do analysts prefer PTPI or ONCO?

Summary

How does Onconetix compare to Vincerx Pharma?

Does the media refer more to ONCO or VINC?

Do insiders & institutionals believe in ONCO or VINC?

Which has better valuation and earnings, ONCO or VINC?

Which has more volatility & risk, ONCO or VINC?

Is ONCO or VINC more profitable?

Do analysts rate ONCO or VINC?

Summary

How does Onconetix compare to Vaxxinity?

Which has preferable valuation and earnings, VAXX or ONCO?

Which has more risk & volatility, VAXX or ONCO?

Do analysts prefer VAXX or ONCO?

Do institutionals and insiders have more ownership in VAXX or ONCO?

Is VAXX or ONCO more profitable?

Does the media prefer VAXX or ONCO?

Summary

How does Onconetix compare to Aditxt?

Do insiders & institutionals believe in ONCO or ADTX?

Which has better valuation & earnings, ONCO or ADTX?

Which has more risk & volatility, ONCO or ADTX?

Is ONCO or ADTX more profitable?

Does the media favor ONCO or ADTX?

Do analysts recommend ONCO or ADTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO vs. The Competition

Onconetix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools